Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10936559 | 0.89 | MPO (0.44) | MEN1KMT2AHDAC1CYP2D6CA1 | |
| SCHEMBL11435601 | 0.81 | LMNA (0.55) | MEN1KMT2AHDAC1NPC1RAB9A | |
| SCHEMBL8656271 | 0.80 | CES2 (0.55) | PTPN1CES2CES1NPC1RAB9A | |
| SCHEMBL8656312 | 0.79 | ALDH1A1 (0.59) | MEN1KMT2ACES2CES1HDAC1 | |
| SCHEMBL1504927 | 0.79 | KDM4E (0.61) | MEN1KMT2AMAOACES2CES1 | |
| SCHEMBL8654622 | 0.79 | CES2 (0.48) | CES2CES1HDAC1NPC1RAB9A | |
| SCHEMBL11435184 | 0.79 | MEN1 (0.50) | MEN1KMT2AMAOAPTPN1CES2 | |
| SCHEMBL1504747 | 0.78 | HDAC3 (0.54) | MEN1KMT2APTPN1CES1HDAC1 | |
| SCHEMBL8654897 | 0.77 | HDAC1 (0.62) | MEN1KMT2ACES2CES1HDAC1 | |
| SCHEMBL10493828 | 0.77 | ALDH1A1 (0.45) | MEN1KMT2AMAOAPTPN1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-2859039-A2 | ODOUR-CONTROL SUPERABSORBENT | BASF SE (DE) | 2015-04-15 | — | — | EP | claimed |
| EP-2701527-A2 | PRODUCTION OF CHESSE WITH S. THERMOPHILUS | Dupont Nutrition Biosciences ApS (DK) | 2014-03-05 | — | — | EP | claimed |
| WO-2013182469-A2 | ODOUR-CONTROL SUPERABSORBENT | BASF SE (DE) | 2013-12-12 | — | — | WO | claimed |
| US-20120288586-A1 | PRODUCTION OF CHEESE WITH S. THERMOPHILUS | DUPONT NUTRITION BIOSCIENCES APS (DK) | 2012-11-15 | — | — | US | claimed |
| WO-2012145629-A2 | PRODUCTION OF CHEESE WITH S. THERMOPHILUS | DANISCO A/S (DK) | 2012-10-26 | — | — | WO | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-4182881-A | N-[Diaminophosphinyl]arylcarboxamides | MORTON-NORWICH PRODUCTS, INC. (US) | 1980-01-08 | — | — | US | claimed |
| WO-2026098996-A1 | ODOR-CONTROL SUPERABSORBENT COMPRISING ACTIVATED CARBON MATERIAL HAVING A TRIMODAL PORE RADIUS DISTRIBUTION | BASF SE (DE) | 2026-05-15 | — | — | WO | disclosed |
| US-12569483-B2 | Methods for objective assessment of memory, early detection of risk for Alzheimer's disease, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2026-03-10 | — | — | US | disclosed |
| US-4289907-A | Process for preparing N-alkyl-nitroanilines | UNION CARBIDE CORPORATION (US) | 1981-09-15 | — | — | US | disclosed |
| US-4182881-A | N-[Diaminophosphinyl]arylcarboxamides | MORTON-NORWICH PRODUCTS, INC. (US) | 1980-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569483-B2 | Methods for objective assessment of memory, early detection of risk for Alzheimer's disease, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs | PSMB3, THRB, GRIN2B | MEN1 4579/4885KMT2A 1593/4885MAOA 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.